Literature DB >> 15525273

Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain.

Steven J R Elmes1, Maulik D Jhaveri, Darren Smart, David A Kendall, Victoria Chapman.   

Abstract

Peripheral cannabinoid 2 receptors (CB2 receptors) modulate immune responses and attenuate nociceptive behaviour in models of acute and persistent pain. The aim of the present study was to investigate whether peripheral CB2 receptors modulate spinal processing of innocuous and noxious responses and to determine whether there are altered roles of CB2 receptors in models of persistent pain. Effects of local administration of the CB2 receptor agonist JWH-133 (5 and 15 microg/50 microL) on mechanically evoked responses of spinal wide dynamic range (WDR) neurons in noninflamed rats, rats with carrageenan-induced hindpaw inflammation, sham operated rats and spinal nerve-ligated (SNL) rats were determined in anaesthetized rats in vivo. Mechanical stimulation (von Frey filaments, 6-80 g) of the peripheral receptive field evoked firing of WDR neurons. Mechanically evoked responses of WDR neurons were similar in noninflamed, carrageenan-inflamed, sham-operated and SNL rats. Intraplantar injection of JWH-133 (15 microg), but not vehicle, significantly (P < 0.05) inhibited innocuous and noxious mechanically evoked responses of WDR neurons in all four groups of rats. In many cases the selective CB2 receptor antagonist, SR144528 (10 microg/50 microL), attenuated the inhibitory effects of JWH-133 (15 microg) on mechanically evoked WDR neuronal responses. The CB1 receptor antagonist, SR141716A, did not attenuate the inhibitory effects of JWH-133 on these responses. Intraplantar preadministration of JWH-133 also inhibited (P < 0.05) carrageenan-induced expansion of peripheral receptive fields of WDR dorsal horn neurons. This study demonstrates that activation of peripheral CB2 receptors attenuates both innocuous- and noxious-evoked responses of WDR neurons in models of acute, inflammatory and neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15525273     DOI: 10.1111/j.1460-9568.2004.03690.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  61 in total

1.  Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice.

Authors:  Hai-Ying Zhang; Ming Gao; Qing-Rong Liu; Guo-Hua Bi; Xia Li; Hong-Ju Yang; Eliot L Gardner; Jie Wu; Zheng-Xiong Xi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

Review 2.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?

Authors:  B B Yao; S Mukherjee; Y Fan; T R Garrison; A V Daza; G K Grayson; B A Hooker; M J Dart; J P Sullivan; M D Meyer
Journal:  Br J Pharmacol       Date:  2006-08-07       Impact factor: 8.739

4.  Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity.

Authors:  I J Lever; T M Pheby; A S C Rice
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

5.  Upregulation of fatty acid amide hydrolase in the dorsal periaqueductal gray is associated with neuropathic pain and reduced heart rate in rats.

Authors:  Caron Dean; Cecilia J Hillard; Jeanne L Seagard; Francis A Hopp; Quinn H Hogan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-02-01       Impact factor: 3.619

6.  In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models.

Authors:  B B Yao; G C Hsieh; J M Frost; Y Fan; T R Garrison; A V Daza; G K Grayson; C Z Zhu; M Pai; P Chandran; A K Salyers; E J Wensink; P Honore; J P Sullivan; M J Dart; M D Meyer
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

7.  Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.

Authors:  Liting Deng; Josée Guindon; Benjamin L Cornett; Alexandros Makriyannis; Ken Mackie; Andrea G Hohmann
Journal:  Biol Psychiatry       Date:  2014-04-25       Impact factor: 13.382

8.  CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.

Authors:  Liting Deng; Benjamin L Cornett; Ken Mackie; Andrea G Hohmann
Journal:  Mol Pharmacol       Date:  2015-04-22       Impact factor: 4.436

Review 9.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

Review 10.  Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain.

Authors:  J Guindon; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.